Inactive Instrument

Other languages Compugen Ltd. Deutsche Boerse AG

Equities

CW9

IL0010852080

Real-time Estimate Tradegate Other stock markets 10:26:50 2024-07-17 EDT			5-day change	1st Jan Change
1.705 ^EUR	-66.24%		-9.82%	0.00%

06-27	Transcript : Compugen Ltd. - Special Call
05-30	Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	05-30
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20
Compugen Names David Silberman CFO	05-15
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-05
Compugen Ltd. Announces Executive Changes	02-15
Sector Update: Health Care Stocks Stronger Late Afternoon	12-19
Sector Update: Health Care	12-19
Looming Inflation Data Stifle US Equity Futures Pre-Bell	12-19
Gilead Sciences, Compugen Sign Exclusive Licensing Deal for Pre-Clinical Immunotherapy Program; Compugen Shares Soar	12-19
Top Midday Gainers	12-19
Top Premarket Gainers	12-19
Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	12-19
Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program	12-19
Compugen Gets Nasdaq Non-Compliance Notice on Minimum Bid Price Rule	11-03
Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer	23-10-31
Sector Update: Health Care Stocks Retreating Monday Afternoon	23-10-02
Compugen Gets Japanese Patent for Cancer Combination Therapy	23-10-02
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer	23-10-02
Compugen Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
Compugen Says European Patent Office Rules in Favor of Maintaining Claims to Patent on Cancer Treatment	23-07-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Compugen Ltd. Deutsche Boerse AG

Equities

CW9

IL0010852080

Other languages

Filters